ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Berlin, BE, DEU:

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Berlin, Germany and 66 other locations

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Berlin, Germany and 75 other locations

of BCL6 (BCL6 LDD), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin...

Enrolling
Relapsed/Refractory Non-Hodgkin Lymphoma
Drug: Rituximab
Drug: BMS-986458

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Berlin, Germany and 21 other locations

monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least tw...

Enrolling
B-cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Drug: AZD0486

Phase 2

AstraZeneca
AstraZeneca

Berlin, Germany and 82 other locations

B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this stud...

Enrolling
Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: ABBV-525

Phase 1

AbbVie
AbbVie

Berlin, Germany and 30 other locations

This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma...

Active, not recruiting
Lymphoma, Non-Hodgkin
Device: Oxaliplatin
Drug: Rituximab

Phase 2, Phase 3

Universität des Saarlandes

Berlin, Germany and 76 other locations

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood ce-...

Enrolling
Hematologic Cancer
Drug: ABBV-101

Phase 1

AbbVie
AbbVie

Berlin, Germany and 37 other locations

in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem ...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: R-GemOx or BR plus polatuzumab vedotin
Genetic: MB-CART2019.1

Phase 2

Miltenyi Biotec
Miltenyi Biotec

Berlin, Germany and 52 other locations

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this dise...

Enrolling
Follicular Lymphoma (FL)
Drug: Lenalidomide
Drug: Epcoritamab

Phase 3

Genmab
Genmab

Berlin, Germany and 281 other locations

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

Phase 3

Loxo Oncology
Loxo Oncology

Berlin, Germany and 216 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems